DVOYNAYa BLOKADA HER2-PETsEPTOPA - NOVOE NAPRAVLENIE V LEChENII RAKA MOLOChNOY ZhELEZY S GIPEREKSPRESSIEY HER2


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

With the advent of trastuzumab, vector of the prognostic significance of tumor marker has been changed for the first time in oncology practice - patients with HER2-positive tumors, previously considered as the most unfavorable, currently have the best prognosis. HER2 blockade strategy has been so successful that now it is the most extensively studying direction in the treatment of breast cancer (BC). The combination of pertuzumab, trastuzumab and docetaxel as first-line therapy for metastatic breast cancer has increased the progression-free survival by 6 months, and the use of trastuzumab as a neoadjuvant therapy has allowed to achieve complete pathological remission in 63 % of cases. Trastuzumab in combination with lapatinib in patients with progression on trastuzumab-containing regimens, has allowed to increase overall survival by 4.5 months; trastuzumab in the neoadjuvant therapy in combination with paclitaxel has allowed to achieve complete pathological remission in 51 % of cases.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

I. Gan'shina

E. Lubennikova

L. Zhukova

Әдебиет тізімі

  1. Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study. 2012; 30(21 ): 2585-92.
  2. Gianni L., Llad A., Bianchi G., et al. Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J. Clin. Oncol. 2010; 28: 1131-37.
  3. Allison D.E., Ng C., Derynck M.K., et al. Pharmacokinetics (PK) of pertuzumab (rhuM-Ab 2C4) in phase II studies of ovarian, breast, prostate, and lung cancers. ASCO Meeting Abstracts. 2005; 23: 2532.
  4. Baselga 4.J., Gelmon K.A., Verma S., et al. Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. J. Clin. Oncol. 2010; 28: 1138-44.
  5. Baselga J., Cortes J., Kim S.-B., et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. The New England journal of medicine. 2012; 366(2).
  6. Ellis P.A., Barrios C.H., Im Y., et al. MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). ASCO Meeting Abstracts. 2011; 29: TPS102.
  7. Swain S.M., Kim S.B., et al. Pertuzumab, trastuzumab and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA STUDY): overall survival results from a randomized, double-blind, placebo-controlled, phase 3 study. April 18,2013. www.thelancet.com/oncology Published online
  8. Rimawi M.F., Poole C.J., et al. Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study PERTAIN). Journal of Clinical Oncology, 2012 ASCO Annual Meeting Abstracts. 2012; 30(15): TPS654.
  9. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer randomized controlled superiority trial with a parallel HER-negative cohort. 2010; 375. www.thelancet.com.
  10. Gianni L., Semiglazov V., Manikhas G., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patient with HER-2 positive locally advanced breast cancer(the NOAH trial): a randomized controlled superiority trial with a parallel HER2-negative cohort. 2010; 375. www.thelancet.com
  11. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomized controlled superiority trial with a parallel HER2-negative control. Lancet Oncol. 2014; 15(Issue 6): 640-47.
  12. Gianni L., Pienkowski T., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicenter, open-label, phase 2 trial. 2012; 13. www.thelancet.com/oncology
  13. Schenewweiss A., Chia S., Hickish T., et al. Perrtuzumab plus trastuzumab in combination with standart neoadjuvant anthracycline-containing or concurrent with anthracycline-free chemotherapy regimens in patients with HER-2 positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals Oncol. 2013; 24: 2278-84.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2014

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>